Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05477524 · ClinicalTrials.gov registry record · Phase 3

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

A Phase 3 study of Lyme Disease, sponsored by Pfizer.

Active
Registry status
Phase 3
Development phase
12,547
Enrollment target
20
Study locations

NCT05477524 is a Phase 3 study of Lyme Disease that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 12,547 participants, above the 2,480-participant average among 9 other Lyme Disease trials with a reported enrollment target (406% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05477524, a Phase 3 study of Lyme Disease, is active but no longer recruiting, sponsored by Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
12,547 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North America and Europe. Approximately 9,400 healthy participants (this number excludes participants from 8 sites which were terminated for quality issues) 5 years and older will be recruited from areas with high levels of endemic Lyme disease to receive VLA15 or placebo (an inactive substance consisting of saltwater). Each participant will have about a 50% chance of receiving VLA15 and about a 50% chance of receiving placebo. A subset of participants will receive VLA15 from 3 different lots or placebo (1:1:1:3 ratio) to assess lot equivalence. Participants will receive a 3-dose primary vaccination series at about 0, 2, and 5 to 9 months and then receive a booster dose about 12 months after end of primary vaccination series. Vaccination of participants will occur at a time of year such that the primary series is completed before the peak Lyme disease season followed by a booster dose just prior to the beginning of the second Lyme disease season. A subset of participants will be followed for a third Lyme disease season. Comparison will be made between the Lyme disease cases of people receiving the study vaccine to those of the people who are not. This will help us determine if the study vaccine is safe and effective. If enrolled, participants will need to visit the research site at least 7 times during the study, and for a subset of participants up to 9 times. There will also be at least 5 telephone contacts. It is expected that each participant will take part in this study for up to about 2 and a half years. The subset of participants followed for a third Lyme disease season will take part in this study for up to about to 3 and a half years.

Conditions Studied

Lyme Disease

Interventions

  • OTHER Saline
  • BIOLOGICAL VLA15

Study Locations (20)

Massachusetts

  • Pediatric Associates of Fall River - Fall River
  • Care Access - Lakeville - Lakeville
  • Care Access - Melrose - Melrose
  • ActivMed Practices and Research - Methuen
  • Care Access - Briarpatch and Mobile Site - Nantucket
  • Care Access - Nantucket - Nantucket
  • Care Access Mobile Site - Nantucket
  • South Shore Medical Center - Norwell

Maryland

  • Johns Hopkins - Baltimore
  • Johns Hopkins Hospital - Baltimore
  • Johns Hopkins Rockland Physician Practice and Research Group - Lutherville
  • Sumit Bhutani MD LLC - Westminster
  • Woodholme Gastroenterology Associates - Westminster

Connecticut

  • Care Access - Essex - Essex
  • Care Access Mobile Site - New London
  • Stamford Health Medical Group - Stamford
  • Stamford Hospital - Stamford

Maine

  • Northern Light Eastern Maine Medical Center - Bangor
  • Care Access - Farmington - Farmington
  • Pen Bay Medical Center - Rockport

Trial Details

FieldValue
Enrollment Target 12,547 participants
Start Date 2022-08-04
Est. Completion 2025-12-26
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05477524

The ClinicalTrials.gov registry entry for NCT05477524 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 12,547 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,480-participant average among 9 other Lyme Disease trials with a reported enrollment target (406% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lyme Disease appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.

NCT05477524 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Maryland, Connecticut.

Frequently Asked Questions

What is clinical trial NCT05477524 about?

NCT05477524 is a clinical study titled "An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)". The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North America and Europe. Approximately 9,400 healthy participants (this number excludes participants from 8 sites which were terminated for quality issues)...

What is the current status of trial NCT05477524?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 12,547 participants. The study started on 2022-08-04. Estimated completion is 2025-12-26.

What conditions does trial NCT05477524 study?

This clinical trial studies the following conditions: Lyme Disease.

What interventions are being tested in trial NCT05477524?

The interventions under investigation include: Saline (OTHER), VLA15 (BIOLOGICAL).

Who is sponsoring clinical trial NCT05477524?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05477524 being conducted?

This trial has 20 study locations across Connecticut, Maine, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lyme Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lyme Disease

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.